Company intelligence / Profile preview

Tecnifar

Lisbon, Portugal

Ownership: Private
Development stage: Other

Overview

Tecnifar is engaged in the research, development, production, and commercialization of proprietary and licensed drugs focused on several therapeutic areas. The company has clinical-stage programs, notably a Phase 2 candidate (TP-102, a bacteriophage therapy for diabetic foot infection, originally from TechnoPhage) and various marketed products in cardiovascular, CNS, respiratory, urology, and other specialties.

Therapeutic areas: Infectious DiseasesEndocrinologyDermatologyNeurology
Modalities: Small moleculeBacteriophage therapy
Industry: Biotech

Drug pipeline

1 asset

cetazolam

Unknown

Partnerships

TechnoPhage

Beyond the preview

Go deeper on Tecnifar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tecnifar.

Explore the full profile